Compare BridgeBio Pharma Inc (BBIO) vs Gitlab Inc (GTLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Gitlab Inc — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.36B), while Gitlab Inc trades at $41.45 (market cap $7.11B). The key difference: BridgeBio Pharma Inc is far larger — about 2.3× Gitlab Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Gitlab Inc nearer its low. Which is the better fit depends on your goals.
| BBIO | GTLB | |
|---|---|---|
Market Cap | $16.36B | $7.11B |
Sector | Health | Technology |
52-Week High | $90.17 | $51.04 |
52-Week Low | $47.29 | $19.42 |
Enterprise Value | $18.14B | $5.85B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Gitlab Inc
GitLab Inc operates on an all-remote model. The company is a technology company whose primary offering is GitLab, a complete DevOps platform delivered as a single application. GitLab is used by a wide range of organizations. The company also provides related training and professional services. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. The principal markets for GitLab are currently located in the United States, Europe, and Asia Pacific. The company is focused on accelerating innovation and broadening the distribution of its platform to companies across the world.
Read more on GTLB →
